Kinetic-driven antibody selection by SPRi delivers optimal precision.
Antibody screening is a critical step in developing high-performance diagnostic assays, yet traditional methods often lack reliability, as selection is typically performed at equilibrium (e.g. ELISA or combinatorial LFA screening).
At Kimialys, we combine the K-One sensor chip with the multiplexing power of SPRi to characterize antibody candidates based on real-time association and dissociation rates. That’s why we call our approach FirstTimeRight, as we guarantee identification of the best antibody — or pair — from the very first screen.
Simplify your workflow by delegating antibody selection to Kimialys. We select your antibodies in just one week, using fewer antibodies and assay materials. This streamlined process saves time, resources, and months of development effort.
Solid-phase immunoassays
LFA / i-PCR
Liquid-phase immunoassays
Turbidimetry / Nephelometry
Target isolation
Immunoprecipitation
Fast antibody selection
We identify the optimal antibodies for your application in just one week — compared to several weeks with conventional approaches.
Unmatched precision
We optimize buffer and immobilization conditions for each antibody and assess cross-reactivity through epitope binning — ensuring no candidates are overlooked.
Minimal reagent usage
Our method requires only small amounts of antibodies and target, making the selection process highly resource-efficient.
Compatible with all detection labels
Our selection process works seamlessly with all label types — such as gold nanoparticles, latex beads, magnetic particles.
Traditionally, antibody selection relies on trial and error, requiring assay developers to go through a labor-intensive screening process. This often involves ELISA or functional assays to evaluate multiple candidates. However, this approach lacks real-time kinetic insights, is time-consuming, and risks missing the most effective antibodies due to suboptimal immobilization or conjugation.
At Kimialys, we leverage the K-One sensor chip together with SPRi's multiplexing capabilities to analyze antibody candidates. That’s the essence of our FirstTimeRight approach: selecting the optimal antibody — or pair — from the very first screen.
Surface Plasmon Resonance imaging (SPRi) is an advanced optical biosensing technology that enables real-time, label-free analysis of molecular interactions. It allows for the simultaneous screening of multiple antibodies on a chip, providing kinetic and affinity data. This multiplexing capability of SPRi significantly saves time but also minimizes the consumption of antibodies and target material.
SPRi also delivers additional analytical value through buffer optimization and validated cross-reactivity testing in real biological samples — such as urine, plasma, serum, or saliva.
Finally, binning analysis — essential for sandwich formats like LFA, iPCR, or ELISA — precisely determines which antibody functions best as capture and which as detection within each compatible pair.
This unique integration of method and technology positions Kimialys at the forefront of antibody screening for diagnostic assays.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique.
Pre-functionalization of SPR sensor chips using K-One® surface chemistry, specifically customized to your applications
Optimal ligand immobilization following Kimialys' proprietary protocol
In-house biomolecular interaction analysis with our own SPRi/SPR platforms
Reliable access to binding and kinetics data, complemented by high-quality reports and presentations, offering actionable insights
We harness both our expertise in SPRi and proprietary K-One® technology on chip to swiftly identify and rank both desired and undesired binding interactions among numerous candidates. This ensures our customers receive consistent and reliable results, accelerating their pursuit of new therapeutics.
We can immobilize any ligands:
Antibodies
Nanobodies
Small molecules
Proteins
DNA/RNA
Whole cells
Peptides
Aptamers
And more...
Our results are consistent and reliable for any complex biological matrices:
Plasma
Serum
Blood
Stem cell supernatant
Hybridoma supernatant
And more...
Reliable measurement of kinetic constants is pivotal for the development of new therapeutics. Leveraging our proprietary K-One® technology, we stand out in the SPR landscape by delivering precise characterization analysis for all biologics and compounds.
Kinetics measured:
Affinity (KD)
Binding rate constants (kon, koff)
Avidity
Pre-functionalization of SPR sensor chips using K-One® surface chemistry, specifically customized to your applications
Optimal ligand immobilization following Kimialys' proprietary protocol
In-house biomolecular interaction analysis with our own SPRi/SPR platforms
Reliable access to binding and kinetics data, complemented by high-quality reports and presentations, offering actionable insights
We harness both our expertise in SPRi and proprietary K-One® technology on chip to swiftly identify and rank both desired and undesired binding interactions among numerous candidates. This ensures our customers receive consistent and reliable results, accelerating their pursuit of new therapeutics.
We can immobilize any ligands:
Antibodies
Nanobodies
Small molecules
Proteins
DNA/RNA
Whole cells
Peptides
Aptamers
And more...
Our results are consistent and reliable for any complex biological matrices:
Plasma
Serum
Blood
Stem cell supernatant
Hybridoma supernatant
And more...
Reliable measurement of kinetic constants is pivotal for the development of new therapeutics. Leveraging our proprietary K-One® technology, we stand out in the SPR landscape by delivering precise characterization analysis for all biologics and compounds.
Kinetics measured:
Affinity (KD)
Binding rate constants (kon, koff)
Avidity
Pre-functionalization of SPR sensor chips using K-One® surface chemistry, specifically customized to your applications
Optimal ligand immobilization following Kimialys' proprietary protocol
In-house biomolecular interaction analysis with our own SPRi/SPR platforms
Reliable access to binding and kinetics data, complemented by high-quality reports and presentations, offering actionable insights
We harness both our expertise in SPRi and proprietary K-One® technology on chip to swiftly identify and rank both desired and undesired binding interactions among numerous candidates. This ensures our customers receive consistent and reliable results, accelerating their pursuit of new therapeutics.
We can immobilize any ligands:
Antibodies
Nanobodies
Small molecules
Proteins
DNA/RNA
Whole cells
Peptides
Aptamers
And more...
Our results are consistent and reliable for any complex biological matrices:
Plasma
Serum
Blood
Stem cell supernatant
Hybridoma supernatant
And more...
Reliable measurement of kinetic constants is pivotal for the development of new therapeutics. Leveraging our proprietary K-One® technology, we stand out in the SPR landscape by delivering precise characterization analysis for all biologics and compounds.
Kinetics measured:
Affinity (KD)
Binding rate constants (kon, koff)
Avidity
Pre-functionalization of sensor chips using K-One® surface chemistry, specifically customized to your applications and analytical platforms
Supply of batches of pre-functionalized sensor chips + ligand immobilization protocol and reagent
For companies looking to manage their own analyses, yet eager to leverage our expertise in chip functionalization and our proficiency in tackling complex analytical challenges.
We provide custom pre-functionalized sensor chips, specifically designed for your ligands, analytical platform, and applications, ensuring that your analyses run smoothly and effectively.
Gold-based sensor types:
For common SPR and SPRi platforms: Biacore, Horiba...
Other SPR-based biosensors: LSPR, Fiber Optic SPR, LR-SPR...
For chip-based diagnostic applications: electrochemical biosensors, QCM...
Our K-One® surface chemistry technology is available for licensing, offering the opportunity to integrate it within your own production environment and standards.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique.
Join our newsletter to stay up to date on features and releases.
By subscribing you agree to with our Privacy Policy and provide consent to receive updates from our company.
